Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $243.8 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, operations-update

TL;DR

Foghorn Therapeutics dropped an 8-K on Jan 13th - check financials and operations updates.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, MA.

Why It Matters

This 8-K filing provides an update on Foghorn Therapeutics' financial condition and operations, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial and operational updates, not indicating any immediate significant risks.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Cambridge, MA (location) — Business address

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

Are there any new material agreements or disclosures mentioned in the Regulation FD section?

The filing states 'Regulation FD Disclosure' is included, but the specific content of these disclosures is not detailed in the provided text.

What types of financial statements and exhibits are included with this 8-K?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific nature of these documents is not elaborated upon in the provided text.

What is Foghorn Therapeutics Inc.'s primary business sector?

Foghorn Therapeutics Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.

When was Foghorn Therapeutics Inc. incorporated and what is its fiscal year end?

The company was incorporated in Delaware and its fiscal year ends on December 31st.

Filing Stats: 915 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-01-13 07:05:09

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
  • $243.8 million — in marketable securities (unaudited) is $243.8 million. On January 13, 2025, the Company iss

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Foghorn Therapeutics Inc. (the "Company") disclosed certain preliminary financial information for the fiscal year ended December 31, 2024 ahead of the 43rd Annual J.P. Morgan Healthcare Conference. Specifically, the Company disclosed that for the fiscal year ended December 31, 2024, the Company's current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) is $243.8 million. On January 13, 2025, the Company issued a press release announcing these preliminary results and other developments. The press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. Additionally, the Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated January 2025, containing these preliminary results, which the Company intends to use in meetings with or presentations to investors. The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2024 or financial condition as of December 31, 2024. The audit of the Company's financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information in this Item 2.02. The information in this Item 2.02 (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information provided in Item 2.02 above is incorporated herein by reference. The information in this Item 7.01 (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K "forward-looking statements." Forward-looking statements include, but are not limited to, statements regarding the Company's preliminary financial statements, and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued on January 13, 2025 99.2 Investor Presentation dated January 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.